Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 1M | 1M | 781K | 929K |
| Gross Profit | 554K | 562K | 628K | 310K | 270K |
| Operating Income | -4M | -5M | -5M | -5M | -6M |
| EBITDA | -4M | -4M | -5M | -4M | -5M |
| Net Income | -4M | -5M | -5M | -4M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.16
-5.88% today
1Y Change
+6.25%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theralase Technologies Inc. (TLTFF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $0.16 and up 6.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -3.4%, EPS growth of +14.9%, a dividend yield of 0.0%. What stands out right now is revenue -3.4%, EPS +14.9%, free cash flow +18.6% with operating margin -440.4% and ROIC -312.1%. Valuation already assumes a fairly strong business story at price/sales 78.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLTFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLTFF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLTFF Max Drawdown
-44.44%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLTFF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$929.1K
+19.0% YoY
FY Net Income
-$5.6M
-26.9% YoY
Free Cash Flow
-$4.6M
-11.6% YoY
Revenue Growth
-3.4%
EPS Growth
+14.9%
Gross Margin
49.3%
Net Margin
-434.9%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 1M | 1M | 781K | 929K |
| Gross Profit | 554K | 562K | 628K | 310K | 270K |
| Operating Income | -4M | -5M | -5M | -5M | -6M |
| EBITDA | -4M | -4M | -5M | -4M | -5M |
| Net Income | -4M | -5M | -5M | -4M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 269K | 44K | 2M | 4M | 8M |
| Total Assets | 3M | 3M | 4M | 6M | 10M |
| Total Liabilities | 1M | 1M | 1M | 875K | 857K |
| Shareholder Equity | 2M | 2M | 3M | 5M | 9M |
| Total Debt | 294K | 387K | 474K | 36K | 92K |
| Net Debt | 25K | 343K | -1M | -4M | -8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-10.3% YoY
Capital Expenditures
165K
-63.2% YoY
Free Cash Flow
5M
-11.6% YoY
Key ratios
Gross Margin
49.3%
Operating Margin
-440.4%
Net Margin
-434.9%
ROE
-315.1%
Debt / Equity
0.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.